nodes	percent_of_prediction	percent_of_DWPC	metapath
Furosemide—CA9—breast cancer	0.29	0.799	CbGaD
Furosemide—ALB—breast cancer	0.0728	0.201	CbGaD
Furosemide—PGD—Methotrexate—breast cancer	0.0675	0.236	CbGbCtD
Furosemide—ABCC2—Tamoxifen—breast cancer	0.0273	0.0955	CbGbCtD
Furosemide—ABCC2—Paclitaxel—breast cancer	0.0212	0.0743	CbGbCtD
Furosemide—ABCC2—Irinotecan—breast cancer	0.0209	0.0733	CbGbCtD
Furosemide—SLC22A11—Methotrexate—breast cancer	0.02	0.0701	CbGbCtD
Furosemide—ABCC2—Carboplatin—breast cancer	0.02	0.0699	CbGbCtD
Furosemide—ABCC2—Vinblastine—breast cancer	0.0186	0.0652	CbGbCtD
Furosemide—ABCC2—Docetaxel—breast cancer	0.0153	0.0537	CbGbCtD
Furosemide—ALB—Irinotecan—breast cancer	0.0131	0.0457	CbGbCtD
Furosemide—ALB—Fluorouracil—breast cancer	0.0125	0.0438	CbGbCtD
Furosemide—SLC22A8—Methotrexate—breast cancer	0.0116	0.0408	CbGbCtD
Furosemide—ABCC2—Doxorubicin—breast cancer	0.0114	0.04	CbGbCtD
Furosemide—ABCC2—Methotrexate—breast cancer	0.0111	0.0388	CbGbCtD
Furosemide—SLC22A6—Methotrexate—breast cancer	0.00811	0.0284	CbGbCtD
Furosemide—ALB—Methotrexate—breast cancer	0.00691	0.0242	CbGbCtD
Furosemide—CA5A—female reproductive system—breast cancer	0.00146	0.0303	CbGeAlD
Furosemide—PGD—mammary gland—breast cancer	0.00144	0.0299	CbGeAlD
Furosemide—CA5B—mammary gland—breast cancer	0.00137	0.0284	CbGeAlD
Furosemide—SLCO2A1—nipple—breast cancer	0.00134	0.0278	CbGeAlD
Furosemide—CA5A—endocrine gland—breast cancer	0.00123	0.0256	CbGeAlD
Furosemide—Indapamide—CA9—breast cancer	0.00121	0.414	CrCbGaD
Furosemide—PGD—nipple—breast cancer	0.00119	0.0248	CbGeAlD
Furosemide—Bumetanide—CA9—breast cancer	0.00106	0.364	CrCbGaD
Furosemide—ALB—mammary gland—breast cancer	0.00106	0.022	CbGeAlD
Furosemide—SLC12A1—epithelium—breast cancer	0.000976	0.0203	CbGeAlD
Furosemide—SLCO2A1—epithelium—breast cancer	0.000901	0.0187	CbGeAlD
Furosemide—SLCO2A1—skin of body—breast cancer	0.000857	0.0178	CbGeAlD
Furosemide—CA9—female reproductive system—breast cancer	0.000851	0.0177	CbGeAlD
Furosemide—SLCO2A1—endometrium—breast cancer	0.000808	0.0168	CbGeAlD
Furosemide—CA14—adrenal gland—breast cancer	0.000788	0.0164	CbGeAlD
Furosemide—CA4—nipple—breast cancer	0.00078	0.0162	CbGeAlD
Furosemide—SLC22A5—mammary gland—breast cancer	0.000769	0.016	CbGeAlD
Furosemide—PGD—skin of body—breast cancer	0.000764	0.0159	CbGeAlD
Furosemide—SLC22A11—female reproductive system—breast cancer	0.000746	0.0155	CbGeAlD
Furosemide—SLCO2A1—uterus—breast cancer	0.000744	0.0155	CbGeAlD
Furosemide—SLCO2A1—pituitary gland—breast cancer	0.000731	0.0152	CbGeAlD
Furosemide—SLCO2A1—adipose tissue—breast cancer	0.000728	0.0151	CbGeAlD
Furosemide—CA9—endocrine gland—breast cancer	0.00072	0.015	CbGeAlD
Furosemide—PGD—endometrium—breast cancer	0.00072	0.0149	CbGeAlD
Furosemide—SLCO2A1—female reproductive system—breast cancer	0.000669	0.0139	CbGeAlD
Furosemide—PGD—uterus—breast cancer	0.000663	0.0138	CbGeAlD
Furosemide—SLCO2A1—adrenal gland—breast cancer	0.000653	0.0136	CbGeAlD
Furosemide—PGD—pituitary gland—breast cancer	0.000651	0.0135	CbGeAlD
Furosemide—PGD—adipose tissue—breast cancer	0.000649	0.0135	CbGeAlD
Furosemide—CA2—nipple—breast cancer	0.000646	0.0134	CbGeAlD
Furosemide—SLC22A5—nipple—breast cancer	0.000636	0.0132	CbGeAlD
Furosemide—SLC22A11—endocrine gland—breast cancer	0.000631	0.0131	CbGeAlD
Furosemide—CA12—female reproductive system—breast cancer	0.00063	0.0131	CbGeAlD
Furosemide—CA5B—adipose tissue—breast cancer	0.000615	0.0128	CbGeAlD
Furosemide—SLCO2A1—female gonad—breast cancer	0.000609	0.0126	CbGeAlD
Furosemide—PGD—female reproductive system—breast cancer	0.000596	0.0124	CbGeAlD
Furosemide—PGD—adrenal gland—breast cancer	0.000582	0.0121	CbGeAlD
Furosemide—SLCO2A1—endocrine gland—breast cancer	0.000566	0.0118	CbGeAlD
Furosemide—CA5B—female reproductive system—breast cancer	0.000565	0.0117	CbGeAlD
Furosemide—PGD—bone marrow—breast cancer	0.000563	0.0117	CbGeAlD
Furosemide—CA5B—adrenal gland—breast cancer	0.000551	0.0114	CbGeAlD
Furosemide—CA1—adipose tissue—breast cancer	0.000543	0.0113	CbGeAlD
Furosemide—PGD—female gonad—breast cancer	0.000543	0.0113	CbGeAlD
Furosemide—CA2—embryo—breast cancer	0.000533	0.0111	CbGeAlD
Furosemide—CA12—endocrine gland—breast cancer	0.000533	0.0111	CbGeAlD
Furosemide—PGD—endocrine gland—breast cancer	0.000505	0.0105	CbGeAlD
Furosemide—CA1—female reproductive system—breast cancer	0.000499	0.0104	CbGeAlD
Furosemide—CA5B—endocrine gland—breast cancer	0.000478	0.00993	CbGeAlD
Furosemide—CA1—bone marrow—breast cancer	0.000471	0.00978	CbGeAlD
Furosemide—CA2—epithelium—breast cancer	0.000435	0.00904	CbGeAlD
Furosemide—ALB—adrenal gland—breast cancer	0.000428	0.00888	CbGeAlD
Furosemide—CA4—pituitary gland—breast cancer	0.000426	0.00884	CbGeAlD
Furosemide—CA4—adipose tissue—breast cancer	0.000424	0.00881	CbGeAlD
Furosemide—CA1—endocrine gland—breast cancer	0.000422	0.00877	CbGeAlD
Furosemide—CA2—skin of body—breast cancer	0.000414	0.0086	CbGeAlD
Furosemide—ABCC2—female reproductive system—breast cancer	0.000411	0.00853	CbGeAlD
Furosemide—SLC22A5—skin of body—breast cancer	0.000407	0.00846	CbGeAlD
Furosemide—ABCC2—adrenal gland—breast cancer	0.000401	0.00832	CbGeAlD
Furosemide—SLCO2A1—lymph node—breast cancer	0.000391	0.00813	CbGeAlD
Furosemide—CA4—female reproductive system—breast cancer	0.00039	0.0081	CbGeAlD
Furosemide—SLC22A5—endometrium—breast cancer	0.000384	0.00797	CbGeAlD
Furosemide—CA4—adrenal gland—breast cancer	0.00038	0.0079	CbGeAlD
Furosemide—CA4—bone marrow—breast cancer	0.000368	0.00764	CbGeAlD
Furosemide—CA4—female gonad—breast cancer	0.000355	0.00737	CbGeAlD
Furosemide—CA2—pituitary gland—breast cancer	0.000353	0.00733	CbGeAlD
Furosemide—CA2—adipose tissue—breast cancer	0.000352	0.0073	CbGeAlD
Furosemide—Indapamide—CYP3A4—breast cancer	0.000349	0.119	CrCbGaD
Furosemide—PGD—lymph node—breast cancer	0.000349	0.00724	CbGeAlD
Furosemide—SLC22A5—pituitary gland—breast cancer	0.000347	0.00722	CbGeAlD
Furosemide—ABCC2—endocrine gland—breast cancer	0.000347	0.00721	CbGeAlD
Furosemide—SLC22A5—adipose tissue—breast cancer	0.000346	0.00719	CbGeAlD
Furosemide—CA5B—lymph node—breast cancer	0.00033	0.00686	CbGeAlD
Furosemide—CA4—endocrine gland—breast cancer	0.00033	0.00685	CbGeAlD
Furosemide—CA2—female reproductive system—breast cancer	0.000323	0.00671	CbGeAlD
Furosemide—SLC22A5—female reproductive system—breast cancer	0.000318	0.00661	CbGeAlD
Furosemide—CA2—adrenal gland—breast cancer	0.000315	0.00655	CbGeAlD
Furosemide—SLC22A5—adrenal gland—breast cancer	0.00031	0.00645	CbGeAlD
Furosemide—CA2—bone marrow—breast cancer	0.000305	0.00634	CbGeAlD
Furosemide—Bumetanide—PTGS2—breast cancer	0.0003	0.103	CrCbGaD
Furosemide—CA2—female gonad—breast cancer	0.000294	0.00611	CbGeAlD
Furosemide—CA1—lymph node—breast cancer	0.000292	0.00606	CbGeAlD
Furosemide—SLC22A5—female gonad—breast cancer	0.000289	0.00601	CbGeAlD
Furosemide—CA2—endocrine gland—breast cancer	0.000274	0.00568	CbGeAlD
Furosemide—ALB—lymph node—breast cancer	0.000256	0.00532	CbGeAlD
Furosemide—ABCC2—lymph node—breast cancer	0.00024	0.00499	CbGeAlD
Furosemide—CA4—lymph node—breast cancer	0.000228	0.00474	CbGeAlD
Furosemide—CA2—lymph node—breast cancer	0.000189	0.00393	CbGeAlD
Furosemide—SLC22A5—lymph node—breast cancer	0.000186	0.00386	CbGeAlD
Furosemide—Agranulocytosis—Epirubicin—breast cancer	5.11e-05	0.000268	CcSEcCtD
Furosemide—Shock—Docetaxel—breast cancer	5.09e-05	0.000268	CcSEcCtD
Furosemide—Nervous system disorder—Docetaxel—breast cancer	5.08e-05	0.000267	CcSEcCtD
Furosemide—Pruritus—Fluorouracil—breast cancer	5.07e-05	0.000267	CcSEcCtD
Furosemide—Thrombocytopenia—Docetaxel—breast cancer	5.07e-05	0.000266	CcSEcCtD
Furosemide—Drowsiness—Doxorubicin—breast cancer	5.07e-05	0.000266	CcSEcCtD
Furosemide—Visual impairment—Methotrexate—breast cancer	5.06e-05	0.000266	CcSEcCtD
Furosemide—Confusional state—Capecitabine—breast cancer	5.05e-05	0.000266	CcSEcCtD
Furosemide—Feeling abnormal—Paclitaxel—breast cancer	5.03e-05	0.000264	CcSEcCtD
Furosemide—Skin disorder—Docetaxel—breast cancer	5.03e-05	0.000264	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Doxorubicin—breast cancer	5.02e-05	0.000264	CcSEcCtD
Furosemide—Gastrointestinal pain—Paclitaxel—breast cancer	4.99e-05	0.000262	CcSEcCtD
Furosemide—Diarrhoea—Gemcitabine—breast cancer	4.99e-05	0.000262	CcSEcCtD
Furosemide—Renal failure—Doxorubicin—breast cancer	4.98e-05	0.000262	CcSEcCtD
Furosemide—Erythema multiforme—Methotrexate—breast cancer	4.97e-05	0.000261	CcSEcCtD
Furosemide—Dizziness—Irinotecan—breast cancer	4.95e-05	0.00026	CcSEcCtD
Furosemide—Anorexia—Docetaxel—breast cancer	4.93e-05	0.000259	CcSEcCtD
Furosemide—Shock—Capecitabine—breast cancer	4.93e-05	0.000259	CcSEcCtD
Furosemide—Nervous system disorder—Capecitabine—breast cancer	4.92e-05	0.000258	CcSEcCtD
Furosemide—Eye disorder—Methotrexate—breast cancer	4.91e-05	0.000258	CcSEcCtD
Furosemide—Diarrhoea—Fluorouracil—breast cancer	4.91e-05	0.000258	CcSEcCtD
Furosemide—Thrombocytopenia—Capecitabine—breast cancer	4.91e-05	0.000258	CcSEcCtD
Furosemide—Tinnitus—Methotrexate—breast cancer	4.9e-05	0.000257	CcSEcCtD
Furosemide—Skin disorder—Capecitabine—breast cancer	4.87e-05	0.000256	CcSEcCtD
Furosemide—Sweating—Doxorubicin—breast cancer	4.86e-05	0.000255	CcSEcCtD
Furosemide—Urinary tract disorder—Epirubicin—breast cancer	4.85e-05	0.000255	CcSEcCtD
Furosemide—Urticaria—Paclitaxel—breast cancer	4.85e-05	0.000255	CcSEcCtD
Furosemide—Hyperhidrosis—Capecitabine—breast cancer	4.85e-05	0.000255	CcSEcCtD
Furosemide—Hypotension—Docetaxel—breast cancer	4.84e-05	0.000254	CcSEcCtD
Furosemide—Abdominal pain—Paclitaxel—breast cancer	4.83e-05	0.000254	CcSEcCtD
Furosemide—Body temperature increased—Paclitaxel—breast cancer	4.83e-05	0.000254	CcSEcCtD
Furosemide—Urethral disorder—Epirubicin—breast cancer	4.82e-05	0.000253	CcSEcCtD
Furosemide—Hepatobiliary disease—Doxorubicin—breast cancer	4.79e-05	0.000252	CcSEcCtD
Furosemide—Anorexia—Capecitabine—breast cancer	4.78e-05	0.000251	CcSEcCtD
Furosemide—Angiopathy—Methotrexate—breast cancer	4.76e-05	0.00025	CcSEcCtD
Furosemide—Vomiting—Mitoxantrone—breast cancer	4.76e-05	0.00025	CcSEcCtD
Furosemide—Vomiting—Irinotecan—breast cancer	4.76e-05	0.00025	CcSEcCtD
Furosemide—Immune system disorder—Methotrexate—breast cancer	4.74e-05	0.000249	CcSEcCtD
Furosemide—Dizziness—Fluorouracil—breast cancer	4.74e-05	0.000249	CcSEcCtD
Furosemide—Visual impairment—Epirubicin—breast cancer	4.74e-05	0.000249	CcSEcCtD
Furosemide—Agranulocytosis—Doxorubicin—breast cancer	4.73e-05	0.000248	CcSEcCtD
Furosemide—Rash—Mitoxantrone—breast cancer	4.72e-05	0.000248	CcSEcCtD
Furosemide—Rash—Irinotecan—breast cancer	4.72e-05	0.000248	CcSEcCtD
Furosemide—Dermatitis—Irinotecan—breast cancer	4.72e-05	0.000248	CcSEcCtD
Furosemide—Dermatitis—Mitoxantrone—breast cancer	4.72e-05	0.000248	CcSEcCtD
Furosemide—Headache—Irinotecan—breast cancer	4.69e-05	0.000247	CcSEcCtD
Furosemide—Headache—Mitoxantrone—breast cancer	4.69e-05	0.000247	CcSEcCtD
Furosemide—Hypotension—Capecitabine—breast cancer	4.68e-05	0.000246	CcSEcCtD
Furosemide—Paraesthesia—Docetaxel—breast cancer	4.65e-05	0.000244	CcSEcCtD
Furosemide—Erythema multiforme—Epirubicin—breast cancer	4.65e-05	0.000244	CcSEcCtD
Furosemide—Vomiting—Gemcitabine—breast cancer	4.64e-05	0.000244	CcSEcCtD
Furosemide—Somnolence—Docetaxel—breast cancer	4.6e-05	0.000242	CcSEcCtD
Furosemide—Rash—Gemcitabine—breast cancer	4.6e-05	0.000242	CcSEcCtD
Furosemide—Dermatitis—Gemcitabine—breast cancer	4.6e-05	0.000241	CcSEcCtD
Furosemide—Eye disorder—Epirubicin—breast cancer	4.59e-05	0.000241	CcSEcCtD
Furosemide—Tinnitus—Epirubicin—breast cancer	4.58e-05	0.000241	CcSEcCtD
Furosemide—Malnutrition—Methotrexate—breast cancer	4.57e-05	0.00024	CcSEcCtD
Furosemide—Erythema—Methotrexate—breast cancer	4.57e-05	0.00024	CcSEcCtD
Furosemide—Headache—Gemcitabine—breast cancer	4.57e-05	0.00024	CcSEcCtD
Furosemide—Vomiting—Fluorouracil—breast cancer	4.56e-05	0.00024	CcSEcCtD
Furosemide—Rash—Fluorouracil—breast cancer	4.52e-05	0.000238	CcSEcCtD
Furosemide—Dermatitis—Fluorouracil—breast cancer	4.52e-05	0.000237	CcSEcCtD
Furosemide—Paraesthesia—Capecitabine—breast cancer	4.5e-05	0.000236	CcSEcCtD
Furosemide—Decreased appetite—Docetaxel—breast cancer	4.5e-05	0.000236	CcSEcCtD
Furosemide—Hypersensitivity—Paclitaxel—breast cancer	4.5e-05	0.000236	CcSEcCtD
Furosemide—Headache—Fluorouracil—breast cancer	4.49e-05	0.000236	CcSEcCtD
Furosemide—Urinary tract disorder—Doxorubicin—breast cancer	4.49e-05	0.000236	CcSEcCtD
Furosemide—Dysgeusia—Methotrexate—breast cancer	4.48e-05	0.000235	CcSEcCtD
Furosemide—Gastrointestinal disorder—Docetaxel—breast cancer	4.47e-05	0.000235	CcSEcCtD
Furosemide—Fatigue—Docetaxel—breast cancer	4.46e-05	0.000235	CcSEcCtD
Furosemide—Angiopathy—Epirubicin—breast cancer	4.46e-05	0.000234	CcSEcCtD
Furosemide—Urethral disorder—Doxorubicin—breast cancer	4.46e-05	0.000234	CcSEcCtD
Furosemide—Nausea—Irinotecan—breast cancer	4.45e-05	0.000234	CcSEcCtD
Furosemide—Nausea—Mitoxantrone—breast cancer	4.45e-05	0.000234	CcSEcCtD
Furosemide—Immune system disorder—Epirubicin—breast cancer	4.44e-05	0.000233	CcSEcCtD
Furosemide—Constipation—Docetaxel—breast cancer	4.43e-05	0.000233	CcSEcCtD
Furosemide—Pain—Docetaxel—breast cancer	4.43e-05	0.000233	CcSEcCtD
Furosemide—Arrhythmia—Epirubicin—breast cancer	4.39e-05	0.000231	CcSEcCtD
Furosemide—Visual impairment—Doxorubicin—breast cancer	4.38e-05	0.00023	CcSEcCtD
Furosemide—Asthenia—Paclitaxel—breast cancer	4.38e-05	0.00023	CcSEcCtD
Furosemide—Decreased appetite—Capecitabine—breast cancer	4.36e-05	0.000229	CcSEcCtD
Furosemide—Nausea—Gemcitabine—breast cancer	4.33e-05	0.000228	CcSEcCtD
Furosemide—Gastrointestinal disorder—Capecitabine—breast cancer	4.33e-05	0.000227	CcSEcCtD
Furosemide—Fatigue—Capecitabine—breast cancer	4.32e-05	0.000227	CcSEcCtD
Furosemide—Pruritus—Paclitaxel—breast cancer	4.32e-05	0.000227	CcSEcCtD
Furosemide—Vision blurred—Methotrexate—breast cancer	4.31e-05	0.000226	CcSEcCtD
Furosemide—Erythema multiforme—Doxorubicin—breast cancer	4.3e-05	0.000226	CcSEcCtD
Furosemide—Pain—Capecitabine—breast cancer	4.29e-05	0.000225	CcSEcCtD
Furosemide—Constipation—Capecitabine—breast cancer	4.29e-05	0.000225	CcSEcCtD
Furosemide—Malnutrition—Epirubicin—breast cancer	4.28e-05	0.000225	CcSEcCtD
Furosemide—Erythema—Epirubicin—breast cancer	4.28e-05	0.000225	CcSEcCtD
Furosemide—Feeling abnormal—Docetaxel—breast cancer	4.27e-05	0.000224	CcSEcCtD
Furosemide—Nausea—Fluorouracil—breast cancer	4.26e-05	0.000224	CcSEcCtD
Furosemide—Eye disorder—Doxorubicin—breast cancer	4.25e-05	0.000223	CcSEcCtD
Furosemide—Tinnitus—Doxorubicin—breast cancer	4.24e-05	0.000223	CcSEcCtD
Furosemide—Gastrointestinal pain—Docetaxel—breast cancer	4.23e-05	0.000222	CcSEcCtD
Furosemide—Anaemia—Methotrexate—breast cancer	4.23e-05	0.000222	CcSEcCtD
Furosemide—Flatulence—Epirubicin—breast cancer	4.22e-05	0.000222	CcSEcCtD
Furosemide—Dysgeusia—Epirubicin—breast cancer	4.19e-05	0.00022	CcSEcCtD
Furosemide—Diarrhoea—Paclitaxel—breast cancer	4.18e-05	0.00022	CcSEcCtD
Furosemide—Feeling abnormal—Capecitabine—breast cancer	4.13e-05	0.000217	CcSEcCtD
Furosemide—Angiopathy—Doxorubicin—breast cancer	4.13e-05	0.000217	CcSEcCtD
Furosemide—Muscle spasms—Epirubicin—breast cancer	4.11e-05	0.000216	CcSEcCtD
Furosemide—Immune system disorder—Doxorubicin—breast cancer	4.11e-05	0.000216	CcSEcCtD
Furosemide—Vertigo—Methotrexate—breast cancer	4.11e-05	0.000216	CcSEcCtD
Furosemide—Gastrointestinal pain—Capecitabine—breast cancer	4.1e-05	0.000215	CcSEcCtD
Furosemide—Body temperature increased—Docetaxel—breast cancer	4.09e-05	0.000215	CcSEcCtD
Furosemide—Abdominal pain—Docetaxel—breast cancer	4.09e-05	0.000215	CcSEcCtD
Furosemide—Leukopenia—Methotrexate—breast cancer	4.09e-05	0.000215	CcSEcCtD
Furosemide—Arrhythmia—Doxorubicin—breast cancer	4.06e-05	0.000213	CcSEcCtD
Furosemide—Dizziness—Paclitaxel—breast cancer	4.04e-05	0.000212	CcSEcCtD
Furosemide—Vision blurred—Epirubicin—breast cancer	4.03e-05	0.000212	CcSEcCtD
Furosemide—Urticaria—Capecitabine—breast cancer	3.98e-05	0.000209	CcSEcCtD
Furosemide—Abdominal pain—Capecitabine—breast cancer	3.96e-05	0.000208	CcSEcCtD
Furosemide—Body temperature increased—Capecitabine—breast cancer	3.96e-05	0.000208	CcSEcCtD
Furosemide—Erythema—Doxorubicin—breast cancer	3.96e-05	0.000208	CcSEcCtD
Furosemide—Malnutrition—Doxorubicin—breast cancer	3.96e-05	0.000208	CcSEcCtD
Furosemide—Anaemia—Epirubicin—breast cancer	3.95e-05	0.000208	CcSEcCtD
Furosemide—Agitation—Epirubicin—breast cancer	3.93e-05	0.000207	CcSEcCtD
Furosemide—Flatulence—Doxorubicin—breast cancer	3.9e-05	0.000205	CcSEcCtD
Furosemide—Vomiting—Paclitaxel—breast cancer	3.88e-05	0.000204	CcSEcCtD
Furosemide—Dysgeusia—Doxorubicin—breast cancer	3.88e-05	0.000204	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.87e-05	0.000203	CcSEcCtD
Furosemide—Rash—Paclitaxel—breast cancer	3.85e-05	0.000202	CcSEcCtD
Furosemide—Dermatitis—Paclitaxel—breast cancer	3.85e-05	0.000202	CcSEcCtD
Furosemide—Vertigo—Epirubicin—breast cancer	3.84e-05	0.000202	CcSEcCtD
Furosemide—Leukopenia—Epirubicin—breast cancer	3.83e-05	0.000201	CcSEcCtD
Furosemide—Headache—Paclitaxel—breast cancer	3.83e-05	0.000201	CcSEcCtD
Furosemide—Hypersensitivity—Docetaxel—breast cancer	3.81e-05	0.0002	CcSEcCtD
Furosemide—Muscle spasms—Doxorubicin—breast cancer	3.81e-05	0.0002	CcSEcCtD
Furosemide—Confusional state—Methotrexate—breast cancer	3.76e-05	0.000198	CcSEcCtD
Furosemide—Anaphylactic shock—Methotrexate—breast cancer	3.73e-05	0.000196	CcSEcCtD
Furosemide—Vision blurred—Doxorubicin—breast cancer	3.73e-05	0.000196	CcSEcCtD
Furosemide—Asthenia—Docetaxel—breast cancer	3.71e-05	0.000195	CcSEcCtD
Furosemide—Hypersensitivity—Capecitabine—breast cancer	3.69e-05	0.000194	CcSEcCtD
Furosemide—Pruritus—Docetaxel—breast cancer	3.66e-05	0.000192	CcSEcCtD
Furosemide—Nervous system disorder—Methotrexate—breast cancer	3.66e-05	0.000192	CcSEcCtD
Furosemide—Anaemia—Doxorubicin—breast cancer	3.66e-05	0.000192	CcSEcCtD
Furosemide—Thrombocytopenia—Methotrexate—breast cancer	3.65e-05	0.000192	CcSEcCtD
Furosemide—Agitation—Doxorubicin—breast cancer	3.64e-05	0.000191	CcSEcCtD
Furosemide—Nausea—Paclitaxel—breast cancer	3.63e-05	0.000191	CcSEcCtD
Furosemide—Skin disorder—Methotrexate—breast cancer	3.62e-05	0.00019	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.62e-05	0.00019	CcSEcCtD
Furosemide—Hyperhidrosis—Methotrexate—breast cancer	3.61e-05	0.00019	CcSEcCtD
Furosemide—Asthenia—Capecitabine—breast cancer	3.6e-05	0.000189	CcSEcCtD
Furosemide—Dry mouth—Epirubicin—breast cancer	3.56e-05	0.000187	CcSEcCtD
Furosemide—Vertigo—Doxorubicin—breast cancer	3.56e-05	0.000187	CcSEcCtD
Furosemide—Anorexia—Methotrexate—breast cancer	3.56e-05	0.000187	CcSEcCtD
Furosemide—Pruritus—Capecitabine—breast cancer	3.55e-05	0.000186	CcSEcCtD
Furosemide—Leukopenia—Doxorubicin—breast cancer	3.54e-05	0.000186	CcSEcCtD
Furosemide—Diarrhoea—Docetaxel—breast cancer	3.54e-05	0.000186	CcSEcCtD
Furosemide—Confusional state—Epirubicin—breast cancer	3.52e-05	0.000185	CcSEcCtD
Furosemide—Anaphylactic shock—Epirubicin—breast cancer	3.49e-05	0.000183	CcSEcCtD
Furosemide—Hypotension—Methotrexate—breast cancer	3.49e-05	0.000183	CcSEcCtD
Furosemide—Shock—Epirubicin—breast cancer	3.44e-05	0.000181	CcSEcCtD
Furosemide—Diarrhoea—Capecitabine—breast cancer	3.43e-05	0.00018	CcSEcCtD
Furosemide—Nervous system disorder—Epirubicin—breast cancer	3.42e-05	0.00018	CcSEcCtD
Furosemide—Dizziness—Docetaxel—breast cancer	3.42e-05	0.00018	CcSEcCtD
Furosemide—Thrombocytopenia—Epirubicin—breast cancer	3.42e-05	0.00018	CcSEcCtD
Furosemide—Skin disorder—Epirubicin—breast cancer	3.39e-05	0.000178	CcSEcCtD
Furosemide—Hyperhidrosis—Epirubicin—breast cancer	3.38e-05	0.000177	CcSEcCtD
Furosemide—Paraesthesia—Methotrexate—breast cancer	3.35e-05	0.000176	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.35e-05	0.000176	CcSEcCtD
Furosemide—Anorexia—Epirubicin—breast cancer	3.33e-05	0.000175	CcSEcCtD
Furosemide—Somnolence—Methotrexate—breast cancer	3.32e-05	0.000174	CcSEcCtD
Furosemide—Dizziness—Capecitabine—breast cancer	3.31e-05	0.000174	CcSEcCtD
Furosemide—Dry mouth—Doxorubicin—breast cancer	3.3e-05	0.000173	CcSEcCtD
Furosemide—Vomiting—Docetaxel—breast cancer	3.29e-05	0.000173	CcSEcCtD
Furosemide—Rash—Docetaxel—breast cancer	3.26e-05	0.000172	CcSEcCtD
Furosemide—Hypotension—Epirubicin—breast cancer	3.26e-05	0.000171	CcSEcCtD
Furosemide—Dermatitis—Docetaxel—breast cancer	3.26e-05	0.000171	CcSEcCtD
Furosemide—Confusional state—Doxorubicin—breast cancer	3.26e-05	0.000171	CcSEcCtD
Furosemide—Decreased appetite—Methotrexate—breast cancer	3.24e-05	0.00017	CcSEcCtD
Furosemide—Headache—Docetaxel—breast cancer	3.24e-05	0.00017	CcSEcCtD
Furosemide—Anaphylactic shock—Doxorubicin—breast cancer	3.23e-05	0.00017	CcSEcCtD
Furosemide—Gastrointestinal disorder—Methotrexate—breast cancer	3.22e-05	0.000169	CcSEcCtD
Furosemide—Fatigue—Methotrexate—breast cancer	3.22e-05	0.000169	CcSEcCtD
Furosemide—Pain—Methotrexate—breast cancer	3.19e-05	0.000168	CcSEcCtD
Furosemide—Vomiting—Capecitabine—breast cancer	3.19e-05	0.000167	CcSEcCtD
Furosemide—Shock—Doxorubicin—breast cancer	3.18e-05	0.000167	CcSEcCtD
Furosemide—Nervous system disorder—Doxorubicin—breast cancer	3.17e-05	0.000166	CcSEcCtD
Furosemide—Thrombocytopenia—Doxorubicin—breast cancer	3.16e-05	0.000166	CcSEcCtD
Furosemide—Rash—Capecitabine—breast cancer	3.16e-05	0.000166	CcSEcCtD
Furosemide—Dermatitis—Capecitabine—breast cancer	3.16e-05	0.000166	CcSEcCtD
Furosemide—Headache—Capecitabine—breast cancer	3.14e-05	0.000165	CcSEcCtD
Furosemide—Skin disorder—Doxorubicin—breast cancer	3.14e-05	0.000165	CcSEcCtD
Furosemide—Paraesthesia—Epirubicin—breast cancer	3.14e-05	0.000165	CcSEcCtD
Furosemide—Hyperhidrosis—Doxorubicin—breast cancer	3.12e-05	0.000164	CcSEcCtD
Furosemide—Somnolence—Epirubicin—breast cancer	3.1e-05	0.000163	CcSEcCtD
Furosemide—Anorexia—Doxorubicin—breast cancer	3.08e-05	0.000162	CcSEcCtD
Furosemide—Nausea—Docetaxel—breast cancer	3.08e-05	0.000162	CcSEcCtD
Furosemide—Feeling abnormal—Methotrexate—breast cancer	3.07e-05	0.000162	CcSEcCtD
Furosemide—Gastrointestinal pain—Methotrexate—breast cancer	3.05e-05	0.00016	CcSEcCtD
Furosemide—Decreased appetite—Epirubicin—breast cancer	3.04e-05	0.000159	CcSEcCtD
Furosemide—Hypotension—Doxorubicin—breast cancer	3.02e-05	0.000159	CcSEcCtD
Furosemide—Gastrointestinal disorder—Epirubicin—breast cancer	3.01e-05	0.000158	CcSEcCtD
Furosemide—Fatigue—Epirubicin—breast cancer	3.01e-05	0.000158	CcSEcCtD
Furosemide—Constipation—Epirubicin—breast cancer	2.99e-05	0.000157	CcSEcCtD
Furosemide—Pain—Epirubicin—breast cancer	2.99e-05	0.000157	CcSEcCtD
Furosemide—Nausea—Capecitabine—breast cancer	2.98e-05	0.000156	CcSEcCtD
Furosemide—Urticaria—Methotrexate—breast cancer	2.96e-05	0.000156	CcSEcCtD
Furosemide—Body temperature increased—Methotrexate—breast cancer	2.95e-05	0.000155	CcSEcCtD
Furosemide—Abdominal pain—Methotrexate—breast cancer	2.95e-05	0.000155	CcSEcCtD
Furosemide—Paraesthesia—Doxorubicin—breast cancer	2.9e-05	0.000152	CcSEcCtD
Furosemide—Feeling abnormal—Epirubicin—breast cancer	2.88e-05	0.000151	CcSEcCtD
Furosemide—Somnolence—Doxorubicin—breast cancer	2.87e-05	0.000151	CcSEcCtD
Furosemide—Gastrointestinal pain—Epirubicin—breast cancer	2.86e-05	0.00015	CcSEcCtD
Furosemide—Decreased appetite—Doxorubicin—breast cancer	2.81e-05	0.000148	CcSEcCtD
Furosemide—Gastrointestinal disorder—Doxorubicin—breast cancer	2.79e-05	0.000147	CcSEcCtD
Furosemide—Fatigue—Doxorubicin—breast cancer	2.79e-05	0.000146	CcSEcCtD
Furosemide—Urticaria—Epirubicin—breast cancer	2.77e-05	0.000146	CcSEcCtD
Furosemide—Pain—Doxorubicin—breast cancer	2.76e-05	0.000145	CcSEcCtD
Furosemide—Constipation—Doxorubicin—breast cancer	2.76e-05	0.000145	CcSEcCtD
Furosemide—Abdominal pain—Epirubicin—breast cancer	2.76e-05	0.000145	CcSEcCtD
Furosemide—Body temperature increased—Epirubicin—breast cancer	2.76e-05	0.000145	CcSEcCtD
Furosemide—Hypersensitivity—Methotrexate—breast cancer	2.75e-05	0.000144	CcSEcCtD
Furosemide—Asthenia—Methotrexate—breast cancer	2.68e-05	0.000141	CcSEcCtD
Furosemide—Feeling abnormal—Doxorubicin—breast cancer	2.66e-05	0.00014	CcSEcCtD
Furosemide—Gastrointestinal pain—Doxorubicin—breast cancer	2.64e-05	0.000139	CcSEcCtD
Furosemide—Pruritus—Methotrexate—breast cancer	2.64e-05	0.000139	CcSEcCtD
Furosemide—Hypersensitivity—Epirubicin—breast cancer	2.57e-05	0.000135	CcSEcCtD
Furosemide—Urticaria—Doxorubicin—breast cancer	2.57e-05	0.000135	CcSEcCtD
Furosemide—Abdominal pain—Doxorubicin—breast cancer	2.55e-05	0.000134	CcSEcCtD
Furosemide—Body temperature increased—Doxorubicin—breast cancer	2.55e-05	0.000134	CcSEcCtD
Furosemide—Diarrhoea—Methotrexate—breast cancer	2.55e-05	0.000134	CcSEcCtD
Furosemide—Asthenia—Epirubicin—breast cancer	2.51e-05	0.000132	CcSEcCtD
Furosemide—Pruritus—Epirubicin—breast cancer	2.47e-05	0.00013	CcSEcCtD
Furosemide—Dizziness—Methotrexate—breast cancer	2.47e-05	0.00013	CcSEcCtD
Furosemide—Diarrhoea—Epirubicin—breast cancer	2.39e-05	0.000126	CcSEcCtD
Furosemide—Hypersensitivity—Doxorubicin—breast cancer	2.38e-05	0.000125	CcSEcCtD
Furosemide—Vomiting—Methotrexate—breast cancer	2.37e-05	0.000125	CcSEcCtD
Furosemide—Rash—Methotrexate—breast cancer	2.35e-05	0.000124	CcSEcCtD
Furosemide—Dermatitis—Methotrexate—breast cancer	2.35e-05	0.000123	CcSEcCtD
Furosemide—Headache—Methotrexate—breast cancer	2.34e-05	0.000123	CcSEcCtD
Furosemide—Asthenia—Doxorubicin—breast cancer	2.32e-05	0.000122	CcSEcCtD
Furosemide—Dizziness—Epirubicin—breast cancer	2.31e-05	0.000121	CcSEcCtD
Furosemide—Pruritus—Doxorubicin—breast cancer	2.29e-05	0.00012	CcSEcCtD
Furosemide—Vomiting—Epirubicin—breast cancer	2.22e-05	0.000117	CcSEcCtD
Furosemide—Nausea—Methotrexate—breast cancer	2.22e-05	0.000116	CcSEcCtD
Furosemide—Diarrhoea—Doxorubicin—breast cancer	2.21e-05	0.000116	CcSEcCtD
Furosemide—Rash—Epirubicin—breast cancer	2.2e-05	0.000116	CcSEcCtD
Furosemide—Dermatitis—Epirubicin—breast cancer	2.2e-05	0.000116	CcSEcCtD
Furosemide—Headache—Epirubicin—breast cancer	2.19e-05	0.000115	CcSEcCtD
Furosemide—Dizziness—Doxorubicin—breast cancer	2.14e-05	0.000112	CcSEcCtD
Furosemide—Nausea—Epirubicin—breast cancer	2.07e-05	0.000109	CcSEcCtD
Furosemide—Vomiting—Doxorubicin—breast cancer	2.05e-05	0.000108	CcSEcCtD
Furosemide—Rash—Doxorubicin—breast cancer	2.04e-05	0.000107	CcSEcCtD
Furosemide—Dermatitis—Doxorubicin—breast cancer	2.04e-05	0.000107	CcSEcCtD
Furosemide—Headache—Doxorubicin—breast cancer	2.02e-05	0.000106	CcSEcCtD
Furosemide—Nausea—Doxorubicin—breast cancer	1.92e-05	0.000101	CcSEcCtD
Furosemide—CA9—Metabolism—TYMS—breast cancer	9.12e-06	8.24e-05	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTGS2—breast cancer	9.12e-06	8.24e-05	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTGS2—breast cancer	9.12e-06	8.24e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—CAV1—breast cancer	9.09e-06	8.22e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—MTHFR—breast cancer	9.06e-06	8.19e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—ALB—breast cancer	9.01e-06	8.15e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PLA2G4A—breast cancer	9.01e-06	8.15e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—NCOR1—breast cancer	9.01e-06	8.15e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—GSTM1—breast cancer	9.01e-06	8.15e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IFNB1—breast cancer	8.98e-06	8.12e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—NCOA2—breast cancer	8.94e-06	8.08e-05	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—RAF1—breast cancer	8.91e-06	8.06e-05	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—ALB—breast cancer	8.91e-06	8.06e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CB—breast cancer	8.88e-06	8.03e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—APRT—breast cancer	8.83e-06	7.98e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—TFRC—breast cancer	8.83e-06	7.98e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTGS2—breast cancer	8.8e-06	7.95e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CD—breast cancer	8.78e-06	7.94e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—CAV1—breast cancer	8.72e-06	7.88e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—SERPINE1—breast cancer	8.68e-06	7.85e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—FASN—breast cancer	8.67e-06	7.84e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—BCHE—breast cancer	8.63e-06	7.8e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—GPX1—breast cancer	8.63e-06	7.8e-05	CbGpPWpGaD
Furosemide—ALB—Selenium Micronutrient Network—IL6—breast cancer	8.63e-06	7.8e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—NOS3—breast cancer	8.62e-06	7.79e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CB—breast cancer	8.59e-06	7.77e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CB—breast cancer	8.59e-06	7.77e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—CYP1A1—breast cancer	8.55e-06	7.72e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTGS2—breast cancer	8.51e-06	7.69e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTGS2—breast cancer	8.51e-06	7.69e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—NCOA2—breast cancer	8.5e-06	7.68e-05	CbGpPWpGaD
Furosemide—PGD—Disease—SRC—breast cancer	8.5e-06	7.68e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—ERCC2—breast cancer	8.48e-06	7.66e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—CAV1—breast cancer	8.36e-06	7.56e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ANGPTL4—breast cancer	8.3e-06	7.51e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ESRRA—breast cancer	8.3e-06	7.51e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CG—breast cancer	8.28e-06	7.49e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PLAUR—breast cancer	8.25e-06	7.46e-05	CbGpPWpGaD
Furosemide—PGD—Disease—STAT3—breast cancer	8.19e-06	7.41e-05	CbGpPWpGaD
Furosemide—CA14—Metabolism—PTEN—breast cancer	8.16e-06	7.38e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—SLC5A5—breast cancer	8.11e-06	7.33e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PLG—breast cancer	8.06e-06	7.29e-05	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—RAF1—breast cancer	8.06e-06	7.29e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—MTHFR—breast cancer	7.97e-06	7.2e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CB—breast cancer	7.96e-06	7.19e-05	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PTEN—breast cancer	7.95e-06	7.19e-05	CbGpPWpGaD
Furosemide—CA6—Metabolism—PTEN—breast cancer	7.95e-06	7.19e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CG—breast cancer	7.94e-06	7.18e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CYP1B1—breast cancer	7.9e-06	7.14e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTGS2—breast cancer	7.89e-06	7.13e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GPI—breast cancer	7.87e-06	7.12e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HADHB—breast cancer	7.87e-06	7.12e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—RAF1—breast cancer	7.84e-06	7.09e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—SLC2A1—breast cancer	7.83e-06	7.08e-05	CbGpPWpGaD
Furosemide—PGD—Disease—MAPK3—breast cancer	7.83e-06	7.08e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—PTEN—breast cancer	7.67e-06	6.93e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PDGFA—breast cancer	7.65e-06	6.92e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CB—breast cancer	7.65e-06	6.92e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CG—breast cancer	7.61e-06	6.88e-05	CbGpPWpGaD
Furosemide—PGD—Disease—MYC—breast cancer	7.61e-06	6.88e-05	CbGpPWpGaD
Furosemide—PGD—Disease—TGFB1—breast cancer	7.59e-06	6.86e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—NCOA1—breast cancer	7.53e-06	6.81e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ALDH7A1—breast cancer	7.51e-06	6.79e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ALDH1A1—breast cancer	7.51e-06	6.79e-05	CbGpPWpGaD
Furosemide—PGD—Disease—EGFR—breast cancer	7.45e-06	6.73e-05	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—ALB—breast cancer	7.44e-06	6.73e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—ITPR1—breast cancer	7.42e-06	6.71e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—PTEN—breast cancer	7.42e-06	6.71e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PTEN—breast cancer	7.42e-06	6.71e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CYP19A1—breast cancer	7.42e-06	6.71e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—ABL1—breast cancer	7.37e-06	6.67e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—CAV1—breast cancer	7.35e-06	6.64e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CD—breast cancer	7.28e-06	6.58e-05	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—ALB—breast cancer	7.21e-06	6.51e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—FHL2—breast cancer	7.2e-06	6.51e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PHGDH—breast cancer	7.2e-06	6.51e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NME1—breast cancer	7.2e-06	6.51e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ADSL—breast cancer	7.2e-06	6.51e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—UMPS—breast cancer	7.2e-06	6.51e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—ALB—breast cancer	7.19e-06	6.5e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—NCOA1—breast cancer	7.16e-06	6.47e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HPSE—breast cancer	7.06e-06	6.38e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—LDHB—breast cancer	7.06e-06	6.38e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—BRIP1—breast cancer	7.06e-06	6.38e-05	CbGpPWpGaD
Furosemide—PGD—Disease—KRAS—breast cancer	7.03e-06	6.36e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—IL2—breast cancer	7.03e-06	6.35e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CD—breast cancer	6.98e-06	6.31e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—PLG—breast cancer	6.98e-06	6.31e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PLA2G4A—breast cancer	6.93e-06	6.27e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—HGF—breast cancer	6.93e-06	6.27e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—ALB—breast cancer	6.89e-06	6.23e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—PTEN—breast cancer	6.88e-06	6.22e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—NOS3—breast cancer	6.88e-06	6.22e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—CSF2—breast cancer	6.86e-06	6.2e-05	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—RAF1—breast cancer	6.73e-06	6.08e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ABCC1—breast cancer	6.69e-06	6.05e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA3—breast cancer	6.69e-06	6.05e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HMMR—breast cancer	6.69e-06	6.05e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CG—breast cancer	6.69e-06	6.05e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CD—breast cancer	6.69e-06	6.05e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—ALB—breast cancer	6.61e-06	5.97e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—NOS3—breast cancer	6.59e-06	5.96e-05	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—RAF1—breast cancer	6.52e-06	5.89e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PPARGC1B—breast cancer	6.48e-06	5.86e-05	CbGpPWpGaD
Furosemide—PGD—Disease—PIK3CA—breast cancer	6.46e-06	5.84e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—HMOX1—breast cancer	6.44e-06	5.82e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CB—breast cancer	6.35e-06	5.74e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—NOS3—breast cancer	6.32e-06	5.71e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	6.31e-06	5.71e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	6.31e-06	5.71e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTGS2—breast cancer	6.29e-06	5.68e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—ABCB1—breast cancer	6.18e-06	5.59e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—SRC—breast cancer	6.13e-06	5.54e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CA9—breast cancer	6.12e-06	5.53e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA4—breast cancer	6.12e-06	5.53e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CB—breast cancer	6.09e-06	5.5e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—GPX1—breast cancer	6.04e-06	5.46e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTGS2—breast cancer	6.03e-06	5.45e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	5.98e-06	5.41e-05	CbGpPWpGaD
Furosemide—PGD—Disease—HRAS—breast cancer	5.98e-06	5.4e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—VEGFA—breast cancer	5.97e-06	5.4e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA2—breast cancer	5.97e-06	5.39e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GPX2—breast cancer	5.97e-06	5.39e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—MMP1—breast cancer	5.9e-06	5.33e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SULT1A1—breast cancer	5.89e-06	5.33e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GPX4—breast cancer	5.89e-06	5.33e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CD—breast cancer	5.88e-06	5.32e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CB—breast cancer	5.83e-06	5.27e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—ALB—breast cancer	5.81e-06	5.25e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—CDK2—breast cancer	5.79e-06	5.23e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PLAU—breast cancer	5.79e-06	5.23e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTGS2—breast cancer	5.78e-06	5.23e-05	CbGpPWpGaD
Furosemide—CA14—Metabolism—PIK3CA—breast cancer	5.76e-06	5.2e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA1—breast cancer	5.76e-06	5.2e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—IDH1—breast cancer	5.76e-06	5.2e-05	CbGpPWpGaD
Furosemide—PGD—Disease—IL6—breast cancer	5.72e-06	5.17e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NAT2—breast cancer	5.69e-06	5.14e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—CAV1—breast cancer	5.65e-06	5.11e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—MAPK3—breast cancer	5.65e-06	5.11e-05	CbGpPWpGaD
Furosemide—CA6—Metabolism—PIK3CA—breast cancer	5.61e-06	5.07e-05	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PIK3CA—breast cancer	5.61e-06	5.07e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—NOS3—breast cancer	5.56e-06	5.02e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PTEN—breast cancer	5.48e-06	4.96e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—TGFB1—breast cancer	5.48e-06	4.96e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CA—breast cancer	5.41e-06	4.89e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—FN1—breast cancer	5.38e-06	4.86e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—NOS2—breast cancer	5.32e-06	4.8e-05	CbGpPWpGaD
Furosemide—PGD—Disease—AKT1—breast cancer	5.28e-06	4.77e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PTEN—breast cancer	5.26e-06	4.75e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CA—breast cancer	5.24e-06	4.73e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CA—breast cancer	5.24e-06	4.73e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CG—breast cancer	5.15e-06	4.65e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CAV1—breast cancer	5.15e-06	4.65e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CB—breast cancer	5.13e-06	4.64e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—EGF—breast cancer	5.09e-06	4.6e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTGS2—breast cancer	5.08e-06	4.59e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PTEN—breast cancer	5.04e-06	4.56e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—MED12—breast cancer	4.99e-06	4.51e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—DPYD—breast cancer	4.99e-06	4.51e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ALDOA—breast cancer	4.91e-06	4.44e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CA—breast cancer	4.85e-06	4.39e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NCOA3—breast cancer	4.77e-06	4.31e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SLC2A2—breast cancer	4.74e-06	4.28e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IGF1—breast cancer	4.71e-06	4.26e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—AKT2—breast cancer	4.71e-06	4.26e-05	CbGpPWpGaD
Furosemide—CA14—Metabolism—AKT1—breast cancer	4.7e-06	4.25e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	4.69e-06	4.24e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CA—breast cancer	4.67e-06	4.22e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—MTR—breast cancer	4.64e-06	4.19e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ABCG2—breast cancer	4.64e-06	4.19e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CPT1A—breast cancer	4.64e-06	4.19e-05	CbGpPWpGaD
Furosemide—CA6—Metabolism—AKT1—breast cancer	4.58e-06	4.14e-05	CbGpPWpGaD
Furosemide—CA5A—Metabolism—AKT1—breast cancer	4.58e-06	4.14e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HPGDS—breast cancer	4.55e-06	4.11e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CD—breast cancer	4.53e-06	4.09e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HBA1—breast cancer	4.52e-06	4.09e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—SERPINE1—breast cancer	4.48e-06	4.05e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PTEN—breast cancer	4.43e-06	4.01e-05	CbGpPWpGaD
Furosemide—PGD—Metabolism—AKT1—breast cancer	4.42e-06	4e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ACHE—breast cancer	4.41e-06	3.99e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTT1—breast cancer	4.41e-06	3.99e-05	CbGpPWpGaD
Furosemide—CA5B—Metabolism—AKT1—breast cancer	4.28e-06	3.87e-05	CbGpPWpGaD
Furosemide—CA7—Metabolism—AKT1—breast cancer	4.28e-06	3.87e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—NOS3—breast cancer	4.27e-06	3.86e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP17A1—breast cancer	4.18e-06	3.78e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTGS1—breast cancer	4.14e-06	3.74e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ENO1—breast cancer	4.14e-06	3.74e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	4.12e-06	3.72e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP2D6—breast cancer	4.06e-06	3.67e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—RAF1—breast cancer	4.04e-06	3.65e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NCOA2—breast cancer	3.98e-06	3.6e-05	CbGpPWpGaD
Furosemide—CA12—Metabolism—AKT1—breast cancer	3.96e-06	3.58e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CB—breast cancer	3.94e-06	3.57e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CA—breast cancer	3.87e-06	3.5e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—FASN—breast cancer	3.86e-06	3.49e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—BCHE—breast cancer	3.84e-06	3.48e-05	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	3.81e-06	3.44e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SLC5A5—breast cancer	3.8e-06	3.43e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CA—breast cancer	3.71e-06	3.35e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—SLC2A1—breast cancer	3.67e-06	3.32e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NQO1—breast cancer	3.67e-06	3.32e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IL2—breast cancer	3.62e-06	3.27e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	3.59e-06	3.25e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP3A4—breast cancer	3.58e-06	3.23e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	3.56e-06	3.22e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CA—breast cancer	3.56e-06	3.21e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP1B1—breast cancer	3.52e-06	3.18e-05	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	3.5e-06	3.16e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HSP90AA1—breast cancer	3.45e-06	3.12e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NCOA1—breast cancer	3.35e-06	3.03e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—STK11—breast cancer	3.31e-06	2.99e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP19A1—breast cancer	3.31e-06	2.99e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—SRC—breast cancer	3.16e-06	2.86e-05	CbGpPWpGaD
Furosemide—CA4—Metabolism—AKT1—breast cancer	3.16e-06	2.86e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CA—breast cancer	3.13e-06	2.83e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.1e-06	2.81e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—VEGFA—breast cancer	3.08e-06	2.78e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—COMT—breast cancer	3.07e-06	2.78e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTP1—breast cancer	3.06e-06	2.77e-05	CbGpPWpGaD
Furosemide—CA2—Metabolism—AKT1—breast cancer	3.03e-06	2.74e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—HMOX1—breast cancer	3.02e-06	2.73e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ITPR1—breast cancer	3.01e-06	2.72e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—MAPK3—breast cancer	2.91e-06	2.63e-05	CbGpPWpGaD
Furosemide—CA1—Metabolism—AKT1—breast cancer	2.91e-06	2.63e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ABCB1—breast cancer	2.9e-06	2.62e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—TYMS—breast cancer	2.84e-06	2.57e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TGFB1—breast cancer	2.83e-06	2.55e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NCOR1—breast cancer	2.81e-06	2.54e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PLA2G4A—breast cancer	2.81e-06	2.54e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTM1—breast cancer	2.81e-06	2.54e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—GPX1—breast cancer	2.69e-06	2.43e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP1A1—breast cancer	2.66e-06	2.41e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—ERCC2—breast cancer	2.64e-06	2.39e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—KRAS—breast cancer	2.62e-06	2.37e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—AKT1—breast cancer	2.55e-06	2.31e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—MTHFR—breast cancer	2.48e-06	2.25e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CA—breast cancer	2.4e-06	2.17e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TP53—breast cancer	2.33e-06	2.1e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—CAV1—breast cancer	2.29e-06	2.07e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—HRAS—breast cancer	2.22e-06	2.01e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.19e-06	1.98e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CG—breast cancer	2.09e-06	1.89e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—AKT1—breast cancer	1.96e-06	1.78e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CD—breast cancer	1.83e-06	1.66e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—NOS3—breast cancer	1.73e-06	1.57e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CB—breast cancer	1.6e-06	1.45e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTGS2—breast cancer	1.58e-06	1.43e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PTEN—breast cancer	1.38e-06	1.25e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CA—breast cancer	9.75e-07	8.81e-06	CbGpPWpGaD
Furosemide—ALB—Metabolism—AKT1—breast cancer	7.97e-07	7.2e-06	CbGpPWpGaD
